Clinical impact of PET/MR FDG-18F in treated colorectal cancer patients

• Grant number: 17/27205-2
• Support Opportunities: Scholarships abroad - Research
• Start date: August 01, 2018
• End date: June 30, 2019
• Field of knowledge: Health Sciences - Medicine - Medical Radiology
• Principal Investigator: Bárbara Juarez Amorim
• Grantee: Bárbara Juarez Amorim
• Host Investigator: Onofrio Antonio Catalano
• Host Institution: Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• Institution abroad: Harvard University, Boston, United States

Abstract

Colorectal cancer is one of the most common cancers worldwide. It is the third most common cancer in men and the second in women. The mortality is higher in the less developed regions of the world. There is a tendency in increasing mortality rates for colorectal cancer until 2025 in Brazil, mostly because of the aging process of the population. Besides, there have been incredible advances in systemic therapy for colorectal cancer, which led to the necessity to monitoring therapy in these patients.PET/CT with 18F-FDG is the state of the art in the evaluation of many cancers. However, it has some limitations as some false positive results and difficulty in evaluate locally spread of rectal cancer (T staging). Magnetic Resonance (MR) is the imaging of choice in staging rectal cancer due to its high anatomical resolution. PET/MR is a new technology, which joint the excellent metabolic capacity from PET with the high anatomical resolution from MR.Purpose: The primary outcome of interest of this project is verify the change in management achieved by PET/RM with 18F-FDG in comparison to the standard care of imaging (CT, MRI and 18F-FDG PET/CT), routinelly performed in clinical practice. Methods: In this retrospective observational diagnostic study, it will be studied patients with colorectal cancer already treated. The eletronic medical records of patients will be evaluated to ascertain if any change in management were prompted by PET/MR comparing to the standard care of imaging. The second outcome of interest will be analyze the performance of PET/MR comparing with the standard care of imaging to determinae the precision of oncologic staging.

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

AMORIM, BARBARA J.; HONG, THEODORE S.; BLASZKOWSKY, LAWRENCE S.; FERRONE, CRISTINA R.; BERGER, DAVID L.; BORDEIANOU, LILIANA G.; RICCIARDI, ROCCO; CLARK, JEFFREY W.; RYAN, DAVID P.; WO, JENNIFER Y.; et al. Clinical impact of PET/MR in treated colorectal cancer patients. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, v. 46, n. 11, p. 2260-2269, OCT 2019. (17/27205-2)